Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
MAZE$34.91+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of cash flows
(in thousands)
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net income (loss) | $52,231 | $(100,415) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Depreciation | 3,297 | 4,089 |
| Stock-based compensation expense | 9,646 | 8,747 |
| Non-cash lease expense | 2,889 | 2,687 |
| Change in fair value of convertible promissory notes | 8,837 | 3,830 |
| Other items, net | 577 | 551 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 93 | 924 |
| Other assets | (2,304) | (35) |
| Accounts payable | (204) | 399 |
| Accrued expenses and other liabilities | 3,807 | (5,092) |
| Operating lease liabilities | (2,915) | (2,512) |
| Net cash provided by (used in) operating activities | 75,954 | (86,827) |
| Investing activities | ||
| Purchases of property and equipment | (1,147) | (441) |
| Net cash used in investing activities | (1,147) | (441) |
| Financing activities | ||
| Payment of deferred offering costs | (3,154) | — |
| Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs | 70,793 | — |
| Proceeds from issuance of convertible promissory notes, net of issuance costs | 24,475 | 16,176 |
| Proceeds from exercise of stock option awards, net of repurchases | 733 | 209 |
| Net cash provided by financing activities | 92,847 | 16,385 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 167,654 | (70,883) |
| Cash, cash equivalents, and restricted cash at beginning of year | 30,246 | 101,129 |
| Cash, cash equivalents, and restricted cash at end of year | $197,900 | $30,246 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Purchases of property and equipment recorded in accounts payable and accrued expenses | $59 | $90 |
| Vesting of restricted stock and stock options subject to repurchase | $23 | $63 |
| Deferred offering costs recorded in accounts payable and accrued expenses | $1,126 | $— |
| Settlement of convertible promissory notes by conversion to Series D-1 redeemable convertible preferred stock | $53,392 | $— |
| Deemed dividend for anti-dilution adjustments to Series B and C redeemable convertible preferred stock upon issuance of Series D redeemable convertible preferred stock | $14,972 | $— |
| Reconciliation to cash, cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $196,812 | $29,158 |
| Restricted cash | $1,088 | $1,088 |
| Total cash, cash equivalents, and restricted cash | $197,900 | $30,246 |
| Supplemental disclosure of cash flow information: | ||
| Income taxes paid | $1,230 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.